Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amcad Biomed's Operating Income for the
three
months ended in Jun. 2026 was NT$-22.48 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-86.68 Mil.
Operating Margin % is calculated as Operating Income divided by its Revenue. Amcad Biomed's Operating Income for the
three
months ended in Jun. 2026 was NT$-22.48 Mil. Amcad Biomed's Revenue for the
three
months ended in Jun. 2026 was NT$6.72 Mil. Therefore, Amcad Biomed's Operating Margin % for the quarter that ended in Jun. 2026 was -334.67%.
Warning Sign:
Amcad Biomed Corp operating margin has been in a 5-year decline. The average rate of decline per year is -28.8%.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Amcad Biomed's annualizedROC % for the quarter that ended in Jun. 2026 was -34.76%.
Amcad Biomed's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -72.40%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Be Aware
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Amcad Biomed Operating Income Related Terms
Amcad Biomed Operating Income Historical Data
* Premium members only.
The historical data trend for Amcad Biomed's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-86.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Income of NT$-86.68 Mil mean?
Amcad Biomed (ROCO:4188) has a Operating Income of NT$-86.68 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Amcad Biomed and its competitors.
Is Amcad Biomed's Operating Income too high?
Amcad Biomed's current Operating Income is NT$-86.68 Mil. Overall, Amcad Biomed has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Operating Income compare to ABT and SYK?
Amcad Biomed's Operating Income of NT$-86.68 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Devices & Instruments company?
A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Amcad Biomed and its competitors. Amcad Biomed's current Operating Income is NT$-86.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$9.54, compared to a current price of NT$14.00 — trading 46.8% above its estimated fair value. The current Operating Income is NT$-86.68 Mil. Amcad Biomed's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Operating Income is NT$-86.68 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$14.00 is trading 46.8% above its estimated GF Value™ of NT$9.54.
GuruFocus considers Amcad Biomed to be Significantly Overvalued.
Key valuation signals for ROCO:4188:
Operating Income: NT$-86.68 Mil
GF Value™: NT$9.54 vs. price of NT$14.00 (46.8% above fair value)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
50GF Score
Get the complete analysis for ROCO:4188
Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
